Compare ELSE & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | AEON |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 25.8M |
| IPO Year | 1995 | N/A |
| Metric | ELSE | AEON |
|---|---|---|
| Price | $7.67 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 7.3K | ★ 64.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,142,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.20 | N/A |
| 52 Week Low | $4.03 | $0.53 |
| 52 Week High | $7.69 | $1.45 |
| Indicator | ELSE | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 82.28 | 37.67 |
| Support Level | $4.56 | $0.70 |
| Resistance Level | $7.68 | $0.83 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 66.67 | 25.36 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.